The market has been down on Heat Biologics Inc (HTBX) stock recently. HTBX gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With HTBX Stock Today?
Heat Biologics Inc (HTBX) stock has risen 1.14% while the S&P 500 has fallen -0.26% as of 1:30 PM on Wednesday, Jun 16. HTBX has risen $0.08 from the previous closing price of $7.02 on volume of 1,321,490 shares. Over the past year the S&P 500 is up 38.12% while HTBX has risen 28.86%. HTBX lost -$1.38 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Heat Biologics Inc click here.
More About Heat Biologics Inc
Heat Biologics Inc is an immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT) form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically modified, irradiated human cancer cells that secrete tumour-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.
Click Here to get the full Stock Score Report on Heat Biologics Inc (HTBX) Stock.